Atlas Molecular Pharma closed a €3 million deal led by Inveready, joined by CDTI, Grupo SPRI, Kereon Partners, Endometrial DIDI, and CRB Inverbio
04 January 2026
04 January 2026
Total investments received (USD): 6.87M
Round value (USD): 3.47M
Company: Atlas Molecular Pharma
Related deals
Aptadel Therapeutics closed a €2 million bridge funding round with Newsight Tech Angels and Little Warrior Foundation
Investments
02 March 2026
D-Sight raised €2M with Clave Capital, Bio Angels Club and ICF - Institut Català de Finances in SPain
Investments
05 February 2026
Belgium
Netherlands
Austria
Germany
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
France
Ireland
Italy
Portugal
United Kingdom